CREON MINIMICROSPHERES 10 10000 UNIT
LIPASE : 10000 UNIT AMYLASE : 11200 UNIT PROTEASE : 730 UNIT · DIN 02200104 · BGP PHARMA ULC
Health Canada status: MARKETED
What is CREON MINIMICROSPHERES 10?
CREON MINIMICROSPHERES 10 10000 UNIT contains LIPASE : 10000 UNIT AMYLASE : 11200 UNIT PROTEASE : 730 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02200104, held by BGP PHARMA ULC, supplied as CAPSULE (DELAYED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Nov-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CREON MINIMICROSPHERES 10 used for?
Treatment of pancreatic exocrine insufficiency (PEI) attributed to cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrectomy, pancreatic cancer, and other pancreatic diseases.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02200104 |
|---|---|
| Brand name | CREON MINIMICROSPHERES 10 |
| Generic / active ingredient | LIPASE : 10000 UNIT AMYLASE : 11200 UNIT PROTEASE : 730 UNIT |
| Manufacturer | BGP PHARMA ULC |
| Strength | 10000 UNIT |
| Dosage form | CAPSULE (DELAYED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) |
| AHFS class | 38:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Nov-2015 |
| Original market date | 1996-08-30 00:00:00 |
How is it administered?
Individualized based on severity of PEI and fat intake. Infants: 2,000-5,000 lipase units/feeding. Adults: 25,000-80,000 lipase units/meal. Max 10,000 units/kg/day. Take with meals/snacks.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at temperatures not exceeding 25°C in a tightly-closed container. Once opened, use within 6 months.
How is it supplied?
MICRO: 20g glass bottles with dosing spoon. Capsules (10, 20, 25, 35): HDPE bottles of 100 capsules.
Contraindications
Hypersensitivity to porcine protein, pancreatic enzymes, or any ingredient in the formulation.
Warnings and precautions
Associated with fibrosing colonopathy at high doses in cystic fibrosis patients. Do not substitute unit-for-unit with other products. Ensure adequate hydration. Potential viral exposure risk.
What can be used instead?
Other Canadian products sharing ATC code A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC). 14 of 65 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COTAZYM | 35000 UNIT | CAPSULE (IMMEDIATE RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00263818 |
| COTAZYM ECS 20 | 25000 UNIT | CAPSULE (DELAYED RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00821373 |
| COTAZYM ECS 8 | 10800 UNIT | CAPSULE (DELAYED RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00502790 |
| CREON MINIMICROSPHERES 25 | 25000 UNIT | CAPSULE (DELAYED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 01985205 |
| CREON MINIMICROSPHERES 35 | 35700 UNIT | CAPSULE (DELAYED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02494639 |
| CREON MINIMICROSPHERES MICRO | 5000 UNIT / 100 MG | GRANULES FOR SUSPENSION, DELAYED RELEASE | BGP PHARMA ULC | MARKETED | DIN 02445158 |
| PANCREASE MT 10 | 43750 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 00789437 |
| PANCREASE MT 16 | 70000 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 00789429 |
| PANCREASE MT 2 | 6200 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 02503433 |
| PANCREASE MT 20 | 37000 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 02503441 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.